Jenscare Biotech Secures Tens of Millions in Series A Funding Led by Chendee Capital to Advance Minimally Invasive Heart Valve Therapies

VCBeat (WeChat ID: vcbeat) has learned that, recently,Innovator in the Field of Minimally Invasive Interventional Therapy for Heart Valves in China—Ningbo Jianshi Biotechnology Co., Ltd. (hereinafter referred to asJianshi Biotech, Jenscare Biotech) completed a Series A financing round of tens of millions of RMB, led by Chende Capital.

Jianshi Biotech is dedicated to innovation in minimally invasive interventional therapies for heart valves. The company has established a management team with a global perspective, led by Ph.D. holders who have returned from overseas. Its core R&D personnel have previously held positions at numerous renowned cardiovascular companies both domestically and internationally, possessing extensive R&D experience in areas such as bioprosthetic valve manufacturing processes and stent design. Adhering to its mission of “safeguarding human heart health with innovative technology,” Jianshi Biotech is committed to becoming a world-class technological leader in interventional heart valve therapy.

Internationally leading and China’s first developed by Jianshi BiotechThe transcatheter tricuspid valve replacement system (Lux-Valve®) fills the gap in domestic tricuspid valve replacement products.At TCT 2017, the most influential international conference on transcatheter technologies held in Denver, USA, in 2017, the debut of Lux-Valve® attracted significant attention from attending experts. The product was expected to enter clinical trials in 2019.

In addition, the company successfully developed a domestically leadingTranscatheter Aortic Valve Replacement System (Ken-Valve®), its unique design ensures that this valve can be used not only for the treatment of aortic stenosis but also for aortic regurgitation (insufficiency). In China, the number of patients with aortic regurgitation caused by aortic insufficiency is no less than that of patients with aortic stenosis. Therefore, this valve is an independently developed achievement that fully aligns with China’s national conditions.

 Internationally Leading, First-in-China Transcatheter Tricuspid Valve Replacement System (Lux-Valve®)

Jianshi Biotechnology was approved for the “Intelligent Team Entrepreneurship Project” by the Ningbo Municipal Science and Technology Bureau of Zhejiang Province in 2013. In 2014, it received the title of “Technological Innovation Team” from the Hangzhou Bay New Area of Ningbo City, Zhejiang Province, along with project funding support. The company’s participation in the project titled “Elimination of Immunogenicity and Anti-Calcification Technologies for Animal-Derived Tissues or Organs” was supported by the National Key R&D Program of the Ministry of Science and Technology in 2016. In the same year, its “Minimally Invasive Interventional Aortic Stent Valve System” project successfully secured funding under the Ningbo Major Industrial Special Project – Life Health Initiative.

Currently, the company has established long-term cooperative relationships with many well-known Grade A tertiary hospitals in China. In 2017, it was honored as an "Outstanding Enterprise" in the national finals of the National Innovation and Entrepreneurship Competition.

Dr. Cao Peng, General Manager of Jianshi Biotech, stated：“Transcatheter Interventional Techniques: A Key Direction for the Future Development of Heart Valve Disease TreatmentCurrently, transcatheter aortic valve intervention has become relatively mature in developed countries, while China is in a period of rapid development. An increasing number of hospitals are performing such procedures, thereby benefiting more patients who previously had no therapeutic options. With the support of national policies advocating independent innovation, domestically developed transcatheter heart valves by Chinese researchers are gradually entering the international arena, achieving leapfrog advancements in many areas.

“Jianshi Biotech has always adhered to the philosophy of independent innovation, focusing on providing comprehensive solutions in the field of minimally invasive interventional heart valve technology based on technological innovation. The decision to partner with Chende Capital for this round of financing stems from Chende’s extensive industry resources in the healthcare sector and its experience in technological innovation, which will significantly accelerate Jianshi Biotech’s R&D and production progress, enabling earlier product launch to benefit the public!”

Wu Jialu, Partner at Chende Capital, remarked“Over the past decade, the field of minimally invasive cardiovascular intervention has experienced a rugged and challenging trajectory. Renal denervation (RDN) and bioresorbable stents, two devices once held in high expectation, have undergone significant setbacks. Transcatheter heart valve interventions have emerged as the only major product category to successfully withstand rigorous scrutiny from basic science, clinical practice, and market validation. Chende Capital has made multiple strategic investments in the cardiovascular intervention sector. While bullish on this direction, the firm is fully aware that the technical barriers involved require long-term accumulation of expertise to overcome.”

“Jianshi Biologics’ founding team has been deeply engaged in the field of cardiovascular intervention for many years, ranking among China’s most seasoned experts in heart valve technology, with a core team demonstrating strong execution capabilities.This strategic partnership between Chende Capital and Jianshi Biotech aims to develop transcatheter heart valves best suited to China’s specific needs, providing optimal solutions for patients with valvular heart disease in the country.”

Source: Official Website of Jianshi Biotech